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Regulated-on-activation-normal-T-cell-expressed-and-secreted (RANTES), a CC-chemokine, enhances antigen-specific T helper (Th) type-1
responses against HIV-1. To evaluate the adjuvant effects of RANTES against HIV vaccine candidate in SHIV-macaque models, we genetically
engineered a live-attenuated SHIV to express the RANTES gene (SHIV-RANTES) and characterized the virus's properties in vivo. After the
vaccination, the plasma viral loads were same in the SHIV-RANTES-inoculated monkeys and the parental nef-deleted SHIV (SHIV-NI)-
inoculated monkeys. SHIV-RANTES provided some immunity in monkeys by remarkably increasing the antigen-specific CD4+ Th cell-
proliferative response and by inducing an antigen-specific IFN-γ ELISpot response. The magnitude of the immunity in SHIV-RANTES-
immunized animals, however, failed to afford greater protection against a heterologous pathogenic SHIV (SHIV-C2/1) challenge compared to
control SHIV-NI-immunized animals. SHIV-RANTES immunized monkeys, elicited robust cellular CD4+ Th responses and IFN-γ ELISpot
responses after SHIV-C2/1 challenge. These findings suggest that the chemokine RANTES can augment vaccine-elicited, HIV-specific CD4+ T
cell responses.
© 2006 Elsevier Inc. All rights reserved.Keywords: SHIV; HIV-1; SIV; RANTES; Adjuvant; Vaccine; ChemokineIntroduction
Development of an effective vaccine against HIV-1 has been
a major priority to control the worldwide AIDS epidemic. To
achieve this goal, several approaches are being tried. Chimeric
simian and human immunodeficiency virus (SHIV) clones
containing the HIV-1 env genes on a simian immunodeficiency
virus (SIV) are useful models for HIV-1 vaccine development,
because SHIVs are readily infectious to macaque monkeys, and
show induction of immune responses to HIV-1 Env. We
previously reported the in vivo properties of SHIV-NM3rN
(derived from HIV-1 NL432 and SIV mac239) with deletion in⁎ Corresponding author. Fax: +81 985 58 7575.
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doi:10.1016/j.virol.2006.10.050the vpx, vpr, and/or nef genes (Igarashi et al., 1998). These
gene-deleted SHIVs are candidates for vaccines against HIV-1
because attenuated SHIVs can induce anti-HIV-1 humoral and
cell-mediated immunity in monkeys without AIDS-like dis-
eases (Haga et al., 1998; Kuwata et al., 2001). Moreover, the
monkeys immunized with the nef-deleted SHIVs (SHIV-NI)
were protected from a challenge with a heterologous pathogenic
SHIV (Enose et al., 2002; Ui et al., 1999). Since live-attenuated
virus vaccines mimic natural exposure to infectious disease,
these vaccines effectively induce very durable humoral and cell-
mediated immunity. Live-attenuated SIV/SHIVs have been
shown to be effective vaccines in macaque models. Although
safety considerations have limited trials of live-attenuated HIV
vaccines in humans (Baba et al., 1999; Gundlach et al., 2000),
determining the mechanism of protection of live-attenuated
Fig. 1. Genetic structures of SHIVs used in this study. (A) The parental SHIV-NI
and SHIV-RANTES. SHIV-NI has some unique restriction enzyme sites in place
of the nef gene of SHIV-NM3rN. SHIV-NM3rN was constructed from HIV-1
NL432 (shaded regions) and SIV mac239 (white regions). The ClaI and ApaI
region of SHIV-NI was replaced by the human RANTES gene (Shimizu et al.,
2006). (B) The challenge virus SHIV-C2/1. SHIV-C2/1 (GenBank accession
number AF217181) was generated by in vivo passage of SHIV-89.6 through
cynomolgus monkeys (Shinohara et al., 1999). SHIV-89.6 was constructed from
HIV-1 HXBc2, HIV-1 89.6, and SIV mac239.
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(Koff et al., 2006; Miller and Abel, 2005). In general, the
immunogenicity of live-attenuated vaccines tends to increase
with increasing virulence (Johnson and Desrosiers, 1998).
Therefore, in attenuating a live virus, there is a trade-off
between safety and immunogenicity. One promising new
strategy to improve immunogenicity of live-attenuated vaccines
is to genetically engineer a virus to co-express an immunosti-
mulatory agent such as a cytokine adjuvant. Several studies
have demonstrated that insertion of a cytokine in gene-deleted
live-attenuated SIV/SHIVs could boost its immunogenicity and
enhance its protection ability (Giavedoni et al., 1997; Stahl-
Hennig et al., 2003). This would make it possible to obtain a
higher level of immunogenicity from safer, less virulent strains.
Chemokines are key players in eliciting immune responses
against viral infections, by selective activation of a subpopula-
tion of immune cells and by attracting these cells to the site of
infection (Luster, 1998). Regulated-on-activation-normal-T-
cell-expressed-and-secreted (RANTES) is a CC-chemokine
and a natural ligand for CC-chemokine receptors (CCRs) 1, 3,
4, and 5. CCR5, the main receptor of RANTES, is expressed
mainly on subsets of monocytes, macrophages, NK cells, and T
lymphocytes that are predominantly associated with T helper
type-1 (Th1) responses (Bonecchi et al., 1998; Loetscher et al.,
1998; Sallusto et al., 1998). An immune response polarized
toward a more Th1 response is associated with a reduced viral
load and non-progression of disease in HIV-1 infection (Imami
et al., 2002). RANTES has been found to enhance cellular
immune responses resulting in a more effective immune-
modulating effect against HIV-1-related virus in rodent and
monkey models (Frauenschuh et al., 2004; Kim et al., 1998;
Waterman et al., 2004; Xin et al., 1999). In addition, infection of
macaques with a live-attenuated SIV induced the production of
CC-chemokines, and the up-regulation of CC-chemokines was
found to be associated with the sterilizing immunity generated
by the vaccine (Ahmed et al., 1999; Gauduin et al., 1999;
Heeney et al., 1998). Moreover, RANTES has been shown to
directly inhibit HIV-1 replication in vitro (Alkhatib et al., 1996;
Cocchi et al., 1995). RANTES blocks or down-modulates
CCR5 in vitro, which leads to suppression of CCR5-tropic (R5-
tropic) HIV-1 infections (Proudfoot et al., 1999). These results
make RANTES an attractive candidate as an immune adjuvant.
In order to test the adjuvant effects of RANTES in SHIV-
macaque models, we previously genetically engineered a SHIV
to co-express the human RANTES gene (SHIV-RANTES) and
characterized its properties in vitro (Shimizu et al., 2006). In a
previous in vitro study, along with the replication of SHIV-
RANTES, RANTES was detected in the culture supernatant at a
maximum level of 98.5 ng/ml in SHIV-RANTES-infected
human CD4+ M8166 cells. The expressed RANTES down-
regulated the expression of CCR5 on PM1 cells, and suppressed
the replication of BaL, a R5-tropic HIV-1.
In this study, we demonstrate that SHIV-RANTES provided
effective cellular immunity in inoculated monkeys by inducing
an antigen-specific proliferation of lymphocytes and by
increasing an antigen-specific gamma interferon (IFN-γ)
enzyme-linked immunospot (ELISpot) response.Results
Immunization of SHIV-NI and SHIV-RANTES
A recombinant SHIV was engineered to express RANTES
(SHIV-RANTES) in place of nef in SHIV-NI (Fig. 1A). To
investigate the in vivo properties of a SHIV-RANTES, four
rhesus monkeys (MM426, MM427, MM430, and MM431)
were intravenously inoculated with 105 tissue culture 50%
infectious dose (TCID50) of SHIV-RANTES, and three animals
(MM428, MM432, and MM434) were inoculated with 105
TCID50 of SHIV-NI as a control. All monkeys were viremic
within 2 weeks post inoculation (wpi) (Fig. 2A). The SHIV-NI
and SHIV-RANTES inoculation induced systemic infection
with similar peak plasma viral RNA (vRNA) levels, reaching
103 to 104 RNA copies/ml at 2 to 4 wpi and falling to almost
below the detection limit by 8 wpi (Figs. 2A and B). This was
also the case for two monkeys (MM346 and MM349) that were
inoculated with the same dose of SHIV-NI in a previous report
(Shimizu et al., 2005). The infectious viruses were transiently
re-isolated at 1 to 6 wpi from co-culture of M8166 cells with
PBMCs (data not shown). The stability of the RANTES gene in
virus isolated from the vaccinated macaques was analyzed by
Fig. 2. Viral loads of SHIVs and RANTES gene stability. (A) Viral RNA loads in plasma of monkeys inoculated with SHIV-RANTES and SHIV-NI. Data for MM346
and MM349 are from a previous report (Shimizu et al., 2005). Plasma viral RNA loads were measured by RT-PCR. The detection limit of this assay was 1.2×102
copies/ml. (B) The geometric mean of viral RNA loads detected in the animals inoculated with SHIV-RANTES (white) and SHIV-NI (black) of each time point is
reported. Values represent the mean with the standard error. (C) Stability of the inserted RANTES gene in SHIV-RANTES, as shown by PCR. DNA plasmids of SHIV-
RANTES (pSHIV-RANTES DNA) and SHIV-NI (pSHIV-NI DNA) were used as the templates of the control. MWM, molecular weight markers of λ-HindIII.
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infected monkeys kept the full-length of the inserted RANTES
gene (Fig. 2C).
Lymphocyte phenotyping of PBMCs
After the infection, the number of peripheral CD4+
lymphocytes remained within the normal level in both the
SHIV-RANTES- and SHIV-NI-inoculated monkeys (Fig. 3A)
and all monkeys clinically remained healthy. Thus, the
pathogenicity of SHIV-RANTES and SHIV-NI infection to
macaque monkeys was not significantly different. No signifi-
cant differences were observed between the SHIV-NI- and
SHIV-RANTES-inoculated monkeys in the cell surface markers
of PBMCs (data not shown).
Expression of RANTES
In SHIV-NI-inoculated monkeys, plasma RANTES levels
were about 2 to 3 ng/ml (Fig. 3B) by enzyme-linked immuno-Fig. 3. Various markers in systemic and local sites in rhesus monkeys after inoculation
cell counts. Values were calculated from the percentage CD3+CD4+ cells measured by
RANTES (MM426, MM427, MM430, MM431) and SHIV-NI (MM428, MM432, M
standard error. (B) Time course of the mean of plasma RANTES levels measured b
chemokine mRNA levels in lymph nodes. MM428 was defined as a standard becaus
chemokine mRNA levels calculated by the ΔΔCT method. Values represent the mesorbent assay (ELISA) throughout the observation period,
which is similar to those in the parental SHIV-NM3rN-
inoculated animals (Kwofie et al., 2000). The plasma RANTES
levels in the SHIV-RANTES-infected monkeys were similar in
SHIV-NI-infected monkeys after the infection. Due to the
limited and local nature of viral replication, we could not detect
the up-regulation of plasma level of RANTES in animals
inoculated with SHIV-RANTES.
Secondary lymphoid tissues are the major sites of replication
of HIV-1-related viruses. Thus, the expressions of RANTES
and several cytokines mRNAs in inguinal lymph nodes from
virus-inoculated monkeys were measured by real-time RT-PCR.
Of note, the mRNA levels of RANTES in the lymph nodes were
modestly higher in SHIV-RANTES-inoculated animals com-
pared to control SHIV-NI-inoculated animals at 2 wpi (Fig. 3C),
whereas the plasma viral loads were about the same in the two
groups. Levels of IFN-γ, as a marker for Th1-type cytokines,
and tumor necrosis factor alpha (TNF-α) mRNAs were higher
in SHIV-RANTES-immunized monkeys than in SHIV-NI-
immunized monkeys. Interleukin-10 (IL-10) and IL-4 mRNAwith SHIV-RANTES (white) and SHIV-NI (black). (A) Time course of CD4+ T
flow cytometry. The mean CD4+ T cell counts of animals inoculated with SHIV-
M434, MM436, MM349) at each time point. Values represent the mean with the
y ELISA. Values represent the mean with the standard error. (C) Cytokines and
e it shows representative data. Data were expressed as the relative cytokine and
an and standard error.
Fig. 5. Antigen-specific IFN-γ ELISpot responses. (A) Number of IFN-γ
secreting PBMCs detected by ELISpot after stimulation with SIV Gag at 2 wpi.
Graph bars represent the mean number of spots per million cells detected in
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levels were almost similar in the two groups. The proviral DNA
loads in the lymph nodes from SHIV-RANTES-infected
monkeys were similar to those in the SHIV-NI-infected
monkeys (data not shown).
Antigen-specific CD4+ Th cell-proliferative response
Chemokines activate polyclonal and antigen-specific helper
T cells during the induction of an immune response (Taub et al.,
1996). To determine whether inoculation of the SHIV-RANTES
elicited antigen-specific lymphocytes in the animals, prolifera-
tive responses to SIV Gag were measured with PBMCs by
uptake of 5-bromo-2′-deoxyuridine (BrdU). In this study,
antigen-specific T cell proliferation was induced especially in
the SHIV-RANTES-inoculated monkeys (example shown in
Fig. 4A). Some SHIV-RANTES-inoculated monkeys demon-
strated polyclonal T cell proliferation even without stimulation,
but the stimulation index (SI) of these monkeys showed a
significant antigen-specific proliferative response (SI>2.0).
Proliferative responses to Gag in the SHIV-RANTES group
were observed as early as 2 wpi (Fig. 4B), while the
proliferative responses to a SIV Gag were low in the SHIV-
NI-inoculated monkeys. These results show that antigen-
specific T cell proliferation was induced markedly in the
SHIV-RANTES group after the infection.Fig. 4. Antigen-specific T cell proliferation responses. (A) Percentage of the SIV
Gag-specific proliferated CD4+ cells (solid bars) and unstimulated cells (open
bars) at 6 wpi, as measured by BrdU uptake. (B) Kinetics of SHIV-specific Th
cell proliferation in SHIV-RANTES- and SHIV-NI-inoculated rhesus monkeys.
Values represent the mean and standard error. Asterisks (*) indicate statistically
significant differences (P<0.05) as determined by the Mann–Whitney U test.
duplicate cultures of PBMCs cultured with SIV Gag, after subtracting the mean
number of spots found in duplicate control cultures of PBMCs in medium alone.
(B) Kinetics of the SIV-Gag-specific IFN-γ ELISpot responses. Values represent
the mean and standard error. Asterisks (*) indicate statistically significant
differences (P<0.05) as determined by the Mann–Whitney U test.Vaccine-induced SHIV-specific IFN-γ ELISpot
Two weeks after the immunizations, responses of SIV-Gag-
specific IFN-γ ELISpot responses were strong in macaques
immunized with SHIV-RANTES, weak in the two of the three
macaques that had been immunized with SHIV-NI, and modest
in the third (MM428) (example shown in Fig. 5A). The
difference in the ELISpot results between SHIV-RANTES and
SHIV-NI groups is statistically significant (P<0.05). In the
SHIV-RANTES-inoculated monkeys, the antigen-specific IFN-
γ ELISpot intensity peaked at 2 wpi and then returned to the
normal low level by 8 wpi (Fig. 5B).
Peptide-based IFN-γ ELISpot assays were shown to be a
reliable way of assessing CD8+ cytotoxic T lymphocytes (CTL)
responses (Schmittel et al., 1997). As no peptides to Gag were
available in our laboratory, we used the protein in this assay. In
order to establish whether CD4+ Th1 cells or CD8+ CTL were
responsible for the IFN-γ production seen in the ELISpot assay,
the SIV-Gag-specific IFN-γ ELISpot responses using CD8+-
depleted PBMCs obtained from monkeys were also assessed.
Although the ELISpot responses varied among the monkeys,
the responses were sustained in PBMCs that were depleted of
CD8+ cells (data not shown). This suggests that the antigen-
specific IFN-γ responses seen in this study were, at least partly
mediated by CD4+ Th1 cells.
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To assess the humoral immune responses in the SHIV-
RANTES and SHIV-NI-immunized monkeys, HIV-1 Env-
specific antibodies (Ab) in the plasma were measured by the
particle agglutination method. The levels of SHIV-specific Abs
began to increase in all the infected animals at 3–5 wpi (Fig. 6).
The kinetics and magnitude of the anti viral Ab response during
the first 6 weeks after vaccination were similar in the two
groups, suggesting that the initiation of the virus-specific Abs
was not different in the two groups. However, in the next 2
weeks, the Ab titers in the SHIV-NI-infected animals continued
to increase (Fig. 6B), whereas the Ab titers in the three of fours
SHIV-RANTES-infected animals remained unchanged or gra-
dually declined (Fig. 6A), resulting in a significant difference in
Ab titers at 8 wpi (P<0.05).
Challenge with a pathogenic SHIV
To evaluate the protective effects provided by SHIV-
RANTES, monkeys were challenged intravenously with 105
TCID50 of heterologous pathogenic SHIV-C2/1 KS661 (Fig.
1B) at 8 wpi. As controls, four naive monkeys (MM298,
MM299, MM338, and MM339) were infected intravenously
with the same dose (105 TCID50) of SHIV-C2/1 KS661. All of
the control SHIV-C2/1-inoculated rhesus monkeys showed a
pronounced decrease of CD4+ T lymphocytes, reaching less
than 50 cells/μl (Fig. 7A). The vRNA in the plasma of the
control monkeys increased to above 107 copies/ml at 1 wpi, and
remained at a high level (Fig. 7B).Fig. 6. Humoral immune responses, as expressed by anti-HIV-1 antibody titer.
Antibody titers in SHIV-RANTES- (A) and SHIV-NI- (B) inoculated rhesus
monkeys were analyzed by particle agglutination assay and are expressed as the
maximum dilution of plasma to give a positive result.After the challenge with a pathogenic SHIV-C2/1, the
circulating CD4+ T cell counts were maintained in all SHIV-
RANTES-immunized monkeys (Fig. 7A). The peak plasma
vRNA loads in the SHIV-RANTES group (104 and 105 copies/
ml) were three orders of magnitude lower than those of the
naive SHIV-C2/1 KS661-inoculated monkeys (Fig. 7B). The
plasma virus loads in three of the four SHIV-RANTES-
immunized monkeys rapidly declined to almost below the
detection limit at 3 weeks post challenge (wpc). The peak
plasma vRNA load of one of the SHIV-NI-immunized monkeys
(MM349; 107 copies/ml) was similar to that of the control
monkeys. The circulating CD4+ T cell count in MM349, a
SHIV-NI-immunized monkey, remained within the normal
range in spite of a transient but intense viremia in the plasma
(Fig. 7A). There was no difference in the nature of the CD4+ T
cell levels and plasma viral RNA loads between SHIV-NI- and
SHIV-RANTES-immunized animals.
Post-challenge anti-SHIV immune responses
We next analyzed the anamnestic cellular and humoral
immune responses against SHIV-C2/1 challenge. At the time of
challenge, similar proportions of SHIV-RANTES- and SHIV-
NI-vaccinated animals had SIV-Gag-specific T cell-proliferative
responses in PBMC. At 1 wpc, all SHIV-RANTES-vaccinated
animals had detectable anti-SHIV-specific T cell-proliferative
responses, while none of the SHIV-NI vaccinated-animals
showed such responses (Fig. 8A). At 2 wpc, antigen-specific T
cell proliferative responses dramatically increased in the SHIV-
RANTES-vaccinated monkeys and only moderately increased
in the SHIV-NI vaccinated-animals. These results suggest that
the CD4+ Th cell proliferation was greatly enhanced in the
SHIV-RANTES-immunized group.
The enhancements of post-challenge anti-SHIV IFN-γ
ELISpot responses were also observed in PBMCs from the
SHIV-RANTES-immunized group as early as 1wpc (Fig. 8B).
Similarly in SHIV-RANTES-vaccinated animals, SHIV-specific
ELISpot responses in all SHIV-NI vaccinated-animals also
could be detected at week 2–3 post-challenge, but the
magnitude of IFN-γ ELISpot responses in SHIV-NI-vaccinated
animals was less than that in the SHIV-RANTES-vaccinated
monkeys. After the post-challenge, the ELISpot response was
markedly higher in the SHIV-RANTES-immunized group than
in the SHIV-NI group (P<0.05).
As for humoral immune response, after the pathogenic
SHIV-C2/1 challenge, the Ab titers of the SHIV-NI-vaccinated
animals and two of the four SHIV-RANTES-vaccinated animals
rose rapidly, while the titers of the other two SHIV-RANTES-
vaccinated animals rose moderately (data not shown).
Quantification of proviral DNA after the pathogenic challenge
To examine the virus clearance in the animals, the proviral
DNAs in the various tissues of the monkeys after the SHIV-C2/1
challenge were measured by quantitative PCR for SHIV-C2/1-
specific SIV vpr regions. Of note, the copy numbers of the
challenge viruses in the tissue samples from the SHIV-RANTES-
Fig. 7. Change in the number of circulating CD4+ T cells (A) and SHIV-C2/1-specific viral RNA loads (B) of the SHIV-NI- and SHIV-RANTES-immunized monkeys
after SHIV-C2/1 challenge. Values are expressed as a percentage of the pre-challenge values of each monkey. Plasma viral RNA loads after the heterologous
pathogenic SHIV (SHIV-C2/1) challenge were measured by RT-PCR. The detection limit of this assay was 1.2×102 copies/ml. Left panels show results for naive
SHIV-C2/1-inoculated monkeys (MM338, MM339, MM298, and MM299) (Shimizu et al., 2005).
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immunized monkeys (Fig. 9A), although the difference was not
statistically significant. For examples, proviral DNAs in the
thymus of the three of four SHIV-RANTES-immunized
monkeys were below the detection limit (<5 copies/μg of total
cellular DNA), while proviral DNAs in the thymus of the SHIV-
NI-immunized monkeys were ranging from 1.2×101 to
1.3×103 copies/μg of total cellular DNA (Fig. 9B). The proviral
DNA load (1.6×102 copies/μg of total cellular DNA) in the
remaining SHIV-RANTES-immunized monkey, MM427, was
similar to that of the SHIV-NI-immunized monkeys (Fig. 9B).
These results show that immunization of SHIV-RANTES may
have immediately eliminated the heterologous challenge virus
from the organs of some monkeys.
Discussion
There is much hope that the worldwide spread of HIV-1 will
be controlled by the development of an HIV-1 vaccine. The
expression of an inserted-cytokine or chemokine gene from a
genetically engineered vaccine virus provides adjuvant effects
locally at the site of virus replication. Several studies have
demonstrated that insertion of a cytokine in a gene-deleted live-
attenuated SIVs could boost the immunogenicity of the viruses
and enhance its protection ability (Giavedoni et al., 1997; Stahl-
Hennig et al., 2003). Although the concept of introducing a
modified live virus as a vaccine is an old one, the concept ofgenetically engineering a virus to co-express an anti-viral agent
should be further examined. Chemokines are secreted during
the generation of an immune response. Release of RANTES has
been reported to enhance the function of HIV-1-specific CTLs.
As an example of the immune adjuvant effect, RANTES
enhanced cellular immune responses resulting in a more
effective immune-modulating effect against HIV-1 in the rodent
and monkey models (Frauenschuh et al., 2004; Kim et al., 1998;
Waterman et al., 2004; Xin et al., 1999). The aim of this study
was to clarify the adjuvant effect of RANTES against HIV-1-
related virus vaccine candidate in a SHIV-macaque model. For
this purpose, we have genetically engineered a nef-deleted
attenuated SHIV to express the RANTES gene, so that when
viral transcription occurs, RANTES will also be produced
locally.
The inoculation of SHIV-RANTES induced a remarkable
antigen-specific CD4+ Th cell-proliferative response. Virus-
specific T helper responses play an important role in
maintaining effective immunity such as CTL responses against
viral pathogens (Kalams and Walker, 1998; Matloubian et al.,
1994). Antigen-specific T cell proliferation is important for the
control of AIDS pathogenesis. HIV-1-specific CD4+ T cell-
proliferative responses have been shown to be inversely related
to viral loads and were initially only observed in long-term
nonprogressors and in individuals who were treated during
acute HIV-1 infection (Rosenberg et al., 1997, 2000). In mice
models, co-injection of RANTES-expressing plasmids with
Fig. 8. Post-challenge antigen-specific immune responses. (A) Antigen-specific T cell proliferation responses after SHIV-C2/1 challenge. Kinetics of SHIV-specific Th
cell proliferation in SHIV-RANTES- and SHIV-NI-inoculated rhesus monkeys after SHIV-C2/1 challenge. (B) Antigen-specific IFN-γ ELISpot responses after SHIV-
C2/1 challenge. Kinetics of the SIV-Gag-specific IFN-γ ELISpot responses in SHIV-RANTES- and SHIV-NI-inoculated rhesus monkeys after SHIV-C2/1 challenge.
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proliferation (Frauenschuh et al., 2004; Kim et al., 1998). Our
results suggest that the co-expression of viral antigen and
RANTES stimulates antigen-specific T cell proliferation, which
may help to increase the antiviral immune response. Similarly,
inoculation with SHIV-RANTES resulted in dramatic changes
in the levels of antigen-specific IFN-γ ELISpot response. Many
studies have shown that chemokine RANTES enhanced cellular
immune responses resulting in a more effective immune-
modulating effect against HIV-1-related virus. Although some
virus-specific immune responses were also elicited in the SHIV-
NI-immunized monkeys, combining the adjuvant RANTES
with a live-attenuated SHIV had a dramatic effect on the cellular
immune responses.
As live-attenuated vaccines, both SHIV-RANTES and
SHIV-NI elicited strong humoral immune responses in
monkeys. Of note, Ab titers in the SHIV-RANTES-vaccinated
monkeys were lower than those in the SHIV-NI-vaccinated
monkeys at the time of challenge. Many studies have reported
that RANTES enhanced the cell-mediated immunity. However,
the effect of RANTES on the humoral immune response is less
clear, with some studies reporting a positive effect (Lillard et al.,
2001; Xin et al., 1999), and others reporting either no effect
(Kim et al., 1998) or a negative effect (Frauenschuh et al.,
2004). In mice models, antibody levels against HIV antigen
were lower in mice injected with plasmids encoding both
RANTES and HIV antigen than in mice injected with plasmidsencoding antigen alone (Frauenschuh et al., 2004). One possible
explanation is that the combination of RANTES and antigen
induced mainly a Th1-biased response, as indicated by a higher
number of IFN-γ secreting cells, resulting in a lower antibody
titers compared to vaccination with antigen alone (Frauenschuh
et al., 2004).
Some studies have shown that RANTES enhanced replica-
tion of CXCR4 (X4)-tropic and R5X4-tropic HIV-1, both of
which depend on a signal transduction and the enhanced HIV-1
replication is associated with increased colocalization of CD4
and CXCR4 (Kinter et al., 1998). Many studies have shown that
RANTES and its analogues suppress the infection of R5-tropic
lentiviruses in vitro. However, little information is available on
the role of RANTES on X4-tropic lentivirus replication. The
over-expression of RANTES may increase the replication of
X4-tropic SHIV. A safety concern about live-attenuated viruses
is that their replication rate may increase. In this regard,
although SHIV-RANTES expressed a high amount of biologi-
cally active RANTES in vitro, we did not observe increased
SHIV replication in either human or monkey cell lines (Shimizu
et al., 2006). The present results show that both SHIV-NI and
SHIV-RANTES replicated at low levels in the infected animals.
Expression of RANTES by SHIV in vivo did not result in
increased viral replication. SHIV vectors containing the
RANTES gene were still attenuated and resulted in mild
infection, and the infected animals were able to induce very
effective immune responses.
Fig. 9. Proviral DNA loads in various tissues of the SHIV-RANTES- and SHIV-
NI-immunized monkeys after the pathogenic SHIV-C2/1 challenge. (A) The
geometric mean of proviral DNA loads detected in the tissues from animals
immunized with SHIV-RANTES (open bars) and SHIV-NI (solid bars) is
reported. Values represent the mean with the standard error. (B) Proviral DNA
loads in thymus of monkeys immunized with SHIV-RANTES and SHIV-NI.
Proviral DNA loads of the challenge viruses were determined by quantitative
PCR and are expressed as viral DNA copy numbers per microgram of total DNA
extracted from the tissue homogenates. The detection limit of this assay was 5
copies/μg of total DNAs. Monkeys were euthanized at 5–6 wpc.
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increase the immunity to a pathogenic virus. The monkeys
immunized with the SHIV-NI were protected from a challenge
with a heterologous pathogenic SHIV (Enose et al., 2002; Ui et
al., 1999). Several studies have demonstrated that insertion of a
cytokine in a gene-deleted live-attenuated SIV could boost its
immunogenicity and enhance its protective ability (Giavedoni et
al., 1997; Stahl-Hennig et al., 2003). In the present study, the
monkeys that received the inoculation of SHIV-RANTES were
partially protected from a challenge with a heterologous
pathogenic SHIV-C2/1. It is important to mention that
PBMCs obtained from SHIV-RANTES-immunized monkeys
after SHIV-C2/1 challenge show robust cellular CD4+ Th
responses and ELISpot responses. A SHIV genetically
engineered to express the RANTES gene enhanced the
anamnestic immune responses against a heterologous patho-
genic SHIV-C2/1 challenge, as well as the primary immune
responses. However, there was no difference in the nature of the
CD4+ T cell levels and plasma viral RNA loads between SHIV-
NI- and SHIV-RANTES-immunized animals, while the proviralDNA loads of the challenge virus in the some SHIV-RANTES-
immunized monkeys were lower than those in the SHIV-NI-
immunized monkeys. The control SHIV-NI, live-attenuated
vaccine candidate also provided protection against pathogenic
SHIV challenge in monkeys. Thus, the impacts on in vitro
measures of cellular immunity do not predict in vivo protection,
in large part because the nef-deleted SHIV is an effective
immunogen. The SHIV-NI-vaccinated monkeys were partially
protected despite the fact that antiviral immune responses were
much weaker after the vaccination than they were in the SHIV-
RANTES-immunized monkeys. The magnitude of virus-
specific CD4+ T cell responses augmented by RANTES in the
SHIV-RANTES-immunized monkeys was not sufficient to
improve the efficacy of the parental vaccine. Either greater
immune augmentation or additional antiviral immune responses
such as CD8+ T cells and neutralizing antibodies may be needed
to truly improve the efficacy of their parental vaccine.
In conclusion, our results suggest that the addition of
RANTES to the SHIV had measurable effects on immunogeni-
city but still did not appear to afford greater protection against
pathogenic SHIV challenge compared to control SHIV-NI-
immunized animals. Additional work is needed to improve the
magnitude and/or quality of these responses to achieve a
measurable effect on vaccine efficacy.
Materials and methods
Viruses
SHIV-NM3rN, having HIV-1 NL432 genes on a SIVmac239
background, was utilized as a starting material. The SHIV-nef
vector designated as SHIV-NI has some restriction enzyme sites
in place of the nef gene of SHIV-NM3rN (Kuwata et al., 2000).
SHIV-NI did not down-modulate CD4+ cells, and did not cause
AIDS like disease in macaques. The human RANTES gene was
inserted into SHIV-NI to generate SHIV-RANTES (Fig. 1A).
The source of the env gene of SHIV-RANTES was a X4-tropic
virus HIV-1 NL432. In vitro, RANTES production by SHIV-
RANTES did not limit replication of the virus (Shimizu et al.,
2006). Virus stocks were prepared with the CD4+ human T cell
line M8166 (a subclone of C8166).
A heterologous pathogenic SHIV-C2/1 KS661 was used for
the challenge virus (Fig. 1B). SHIV-C2/1 KS661 is a molecular
clone derived from SHIV-C2/1 (GenBank accession number
AF217181), and causes rapid CD4+ T cell depletion (Shinohara
et al., 1999). The env gene of SHIV-C2/1 was derived from
HIV-1 89.6, and is antigenically different from the env gene of
SHIV-NI and SHIV-RANTES.
Immunization and challenge
Male rhesus macaques (Macaca mulatta) were cared for at
the Institute for Virus Research, Kyoto University in accordance
with regulations approved by the Institutional Animal Care and
Use Committee of the Institute for Virus Research, Kyoto
University. Seven animals were divided into two groups: SHIV-
RANTES (MM426, MM427, MM430, and MM431; n=4) and
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were inoculated intravenously with 105 TCID50 of each virus.
At 8 wpi, all animals were challenged intravenously with a 105
TCID50 of pathogenic SHIV-C2/1 KS661. Citrate-anticoagulant
blood samples were collected under anesthesia with ketamine
hydrochloride. Blood samples were phenotypically character-
ized on a FACSCaliber flow cytometer (Becton Dickinson, San
Jose, CA) and were separated into plasma and peripheral blood
mononuclear cells (PBMCs) by Ficoll density centrifugation
(Nacalai Tesque, Inc. Kyoto, Japan). Inguinal lymph nodes were
obtained from these animals by biopsy at 2 wpi and before
infection. Single-cell suspensions were prepared from the
inguinal lymph nodes with a 100 μm nylon cell strainer
(Becton Dickinson). Data from two monkeys (MM346 and
MM349) that were inoculated with the same dose of SHIV-NI in
a previous report (Shimizu et al., 2005) were also utilized. Data
from four naive monkeys (MM298, MM299, MM338, and
MM339) that were infected intravenously with the same dose
(105 TCID50) of SHIV-C2/1 KS661, were used as control
(Shimizu et al., 2005).
Lymphocyte immunophenotyping
Anticoagulated whole-blood specimens or lymphocytes
obtained from peripheral lymph node biopsies were immuno-
phenotyped with the following monoclonal antibodies
(MAbs): anti-CD4 (Nichirei, Tokyo, Japan), anti-CD8 (Becton
Dickinson), anti-CD3 (BioSource International), anti-CD20
(Becton Dickinson), anti-CD14 (Beckman Coulter, Miami, FL),
anti-CCR5 (Pharmingen, San Diego, CA), anti-CXCR4 (Phar-
mingen), anti-CD28 (Pharmingen), anti-CD95 (Pharmingen),
anti-CD69 (Pharmingen), anti-CD80 (Pharmingen), anti-
CD154 (Pharmingen), anti-CD212 (Pharmingen), and anti-
HLA-DR (Pharmingen). Ten thousand events per sample were
acquired by the FACSCaliber, and data were analyzed by
CellQuest software (Becton Dickinson) and FlowJo software
(TreeStar, San Carlos, CA). Absolute lymphocyte counts on
blood specimens were obtained with an automated hematology
analyzer (F-820; Sysmex, Kobe, Japan). Peripheral blood
CD4+ T lymphocytes counts were calculated by multiplying
the total lymphocyte count by the percentage of CD3+CD4+ T
cells.
Plasma viral RNA loads
Plasma viral RNA loads were determined by quantitative RT-
PCR as described previously (Enose et al., 2002; Suryanarayana
et al., 1998). Total RNAs were prepared from plasma with a
QIAamp viral RNA kit (QIAGEN, Valencia, CA), and RT-PCR
was performed using a Platinum Quantitative RT-PCR Thermo-
Script one-step system kit (Invitrogen Corp., Carlsbad, CA).
The plasma viral loads of SHIV-NI, SHIV-RANTES, and the
challenge virus were differentially evaluated with primer pairs
specific to SHIV-NM3rN and SHIV-C2/1, respectively (Enose
et al., 2004). These reactions were performed with a Prism 7700
Sequence Detector (Applied Biosystems, Foster City, CA) and
analyzed using the manufacturer's software.Virus isolation
To isolate the virus, CD8+-depleted PBMCswere co-cultured
with M8166 cells, as described previously (Enose et al., 2004).
CD8+-depleted PBMCs were obtained from each monkey by
using mouse anti-human CD8 MAb (Nichirei, Japan) and sheep
anti-mouse IgG magnetic beads (Dynabeads M-450; Dynal A.
S., Oslo, Norway). Viral recovery, based on the syncytium
formation, was monitored for 4 weeks.
Isolation of proviral DNA
Proviral DNAwas extracted from 1×106 PBMCs and tissues
of the inoculated monkeys. When the virus was re-isolated,
CD8+-depleted PBMCs, which were co-cultured with M8166
cells, were also monitored. Cellular DNAs were extracted using
DNeasy tissue kits (QIAGEN). To check the stability of inserted
RANTES gene in SHIV-RANTES, the proviral DNA fragments
covering the inserted RANTES gene in SHIV-RANTES were
amplified by PCR with primers specific for the nef region
(Kuwata et al., 2000; Shimizu et al., 2006). The lengths of DNA
fragments generated by this reaction were 415 bp for the SHIV
containing the intact RANTES gene and 154 bp for SHIV-NI. The
proviral DNA loads were determined by quantitative PCR. PCR
was performed with a Taqman PCR reagent kit (Perkin Elmer)
using the same primer and probe which were used in RT-PCR. A
standard curve was generated from a plasmid DNA sample
containing the full genome of SHIV-NM3rN or SHIV-C2/1
KS661, which was quantified with a UV-spectrophotometer.
Determination of plasma level of RANTES
Plasma RANTES concentration was measured using a
human RANTES ELISA kit (R&D Systems, Inc., Minneapolis,
MN), which is known to cross-react with rhesus RANTES
(Kwofie et al., 2000). Because chemokine gene transcription
can change dramatically during storage of whole blood for
periods of as little as 6 h (Tanner et al., 2002), platelet-poor
plasma was prepared from whole blood samples within 2 h by
centrifugation at 10,000×g for 10 min at 4 °C according to the
manufacturer's recommendation. Samples that had been
aliquoted and stored at −80 °C were thawed immediately
before assay and were not reused.
Chemokine and cytokine mRNA analysis by real-time PCR
amplification
Inguinal lymph nodes suspensions were collected from
rhesus macaques at the time of biopsy. Total RNAwas isolated
using an RNA Mini kit (Qiagen). All samples were DNase
(Qiagen)-treated for 20 min at 37 °C. cDNAwas prepared using
random hexamer primers (Invitrogen) and M-MLV-Reverse-
Transcriptase (Super Script III, Invitrogen). Real-time PCR
amplifications were conducted by SYBR Green methods.
Oligonucleotide primers were designed for the TaqMan assay
based on previously published reports (Abel et al., 2001;
Hofmann-Lehmann et al., 2002). The following primers were
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AGCCATCACTTGGATGAGTTCA), IL-2 (F, CACCAGGAT-
GCTCACATTTAAGTT;R,GAGGTTTGAGTTCTTCTTCTA-
GACACTGA), IL-4 (F, AAACGGCTCGACAGGAACCT; R
CTCTGGTTGGCTTCCTTCACA), IL-10 (F, CACGACCCA-
GACATCAAGGA;R, CCACGGCCTTGCTCTTGTT), TNF-α
(F, GGCTCAGGCAGTCAGATCATC; R, GCTTGAG-
GGTTTGCTACAACATG), RANTES (F, ACCAGTGG-
CAAGTGCTCCA; R, TGGCACACACTTGGCGATT), and
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (F,
GCACCACCAACTGCTTAGCAC; R, TCTTCTGGGTGG-
CAGTGATG). Primers were used at a final concentration of
50 or 300 nM. The reaction was carried out in a 25 μl reaction
volume containing appropriate diluted 5 μl of cDNAwith SYBR
Green PCR master Mix (Applied Biosystems). All sequences
were amplified using the following amplification program:
2 min at 50 °C, 10 min at 95 °C, followed by 50 to 55 cycles of
15 s at 95 °C and 1 min at 60 °C with a Prism 7700 or 7000
Sequence Detector (Applied Biosystems). Samples were tested
in duplicate, and the PCR for the housekeeping gene (GAPDH)
and the target (cytokine or chemokine) gene was run in parallel
on the same plate. The relative quantities of cytokine mRNA
transcripts were determined by comparative threshold cycle (CT)
methods (ΔΔCT methods) (Pfaffl, 2001). In this analysis, theCT
value for the housekeeping gene is subtracted from the CT value
of the target gene (ΔCT). The target gene and the housekeeping
gene were amplified with the same efficiency (data not shown).
The mRNA samples from one SHIV-NI-immunized monkey,
MM428, were defined as a standard. ΔΔCT values were cal-
culated as follows: ΔΔCT=ΔCT value for each individual
monkey-ΔCT value of standard monkey. Then, the relative
quantitation of cytokine mRNA expression level was calculated
by 2−ΔΔCT.
Proliferation assays
Lymphocyte proliferation was measured by incorporation of
BrdU into the stimulated-lymphocytes (Shimizu et al., 2005).
PBMCs (2×105) were cultured in a 96-well plate in RPMI 1640
with 10% FCS (complete RPMI medium). The recombinant
viral proteins of SIV Gag (SIVmac251 p27; 5.0 μg/ml;
Advanced Biotechnologies, Inc., Columbia, MD) were used
for antigen-specific stimulation. Concanavalin A (ConA;
0.5 μg/ml; Sigma, St. Louis, MO) was used for polyclonal
stimulation. The plates were incubated for 72 h at 37 °C. After
the incubation, the cells were cultured for another 24 h in the
presence of BrdU. Then lymphocyte proliferation was measured
using a BrdU-Flow kit (Pharmingen) following the manufac-
turer's recommendations. To characterize the lymphocyte
subsets in the proliferated cells, cells were stained for surface
markers with MAb CD4-PE (Nichirei) and CD8-PerCP (Becton
Dickinson). The cells were stained with MAb BrdU-FITC after
fixation and permeabilization, and then analyzed by FACScan
(Becton Dickinson). Proliferation responses to the antigens
were considered positive if the stimulation index (SI= titers for
antigen-stimulated samples / titers for control samples without
antigens) exceeded 2.0 (Shimizu et al., 2005).IFN-γ ELISpot
The frequency of antigen-specific IFN-γ-producing cells
from PBMCs was determined by ELISpot analysis. The IFN-γ
ELISpot assaywas conducted according to the protocol provided
by the manufacturer (Mabtech, Nacka Strand, Sweden). Briefly,
96-well Multiscreen-IP plates (Multiscreen MAIPS45-10,
Millipore, Bedford, MA) were coated with 15 μg/ml anti-IFN-
γMab in sterilized phosphate-buffered saline (PBS) overnight at
4 °C. Then, PBMCs were incubated with or without 5 μg/ml of
SIV Gag for 24 h at 37 °C and were added to the pre-coated
plates at 2.0 and 5.0×105 cells/well in complete RPMI medium.
Experiments were performed in duplicate wells. PBMCs which
were incubatedwith 0.5 μg/ml of ConA for 2 h at 37 °Cwere also
used as a polyclonal stimulation. Plates were incubated for about
36 h at 37 °C. Following incubation, cells were removed, and
residual cells were lysed with ice-cold water for 10 min.
Biotinylated anti-IFN-γ monoclonal antibody was added and
incubated for 3 h at room temperature, followed by addition of
streptavidin-horseradish peroxidase for 2 h at room temperature.
Spots were developed with a Vector NovaRED™ Substrate kit
for peroxidase (Vector Labs, CA). The number of spot-forming
cells was determined by using a light microscope. The average
number of spots present in the non-stimulated cultures was
subtracted from the average number in the antigen-stimulated
cultures.
Determination of anti-SHIV antibody titers
Anti-SHIVantibody titers in the plasma of the monkeys were
determined using a commercial particle agglutination test kit
(Genedia HIV-1/2, Fujirebio Inc., Tokyo, Japan). The samples
were serially two-fold diluted and assayed following the
manufacturer's recommendations. The end-point titer was
determined as the highest dilution to give a positive result.
Statistical analysis
Differences between the SHIV-RANTES- and SHIV-NI-
inoculated monkeys were analyzed with the Mann–Whitney U
test. P values <0.05 were considered statistically significant.
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